Pharmamarketeer
FDA Drug Approval Decisions Expected in February 2024

FDA Approves Talzenna for Metastatic Castration-Resistant Prostate Cancer

FDA Approves Talzenna for Metastatic Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Approval of Talzenna was granted to Pfizer.

Medhc-fases-banner
Advertentie(s)